clinical trial · NCT07170995
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·recruiting·n = 460
Advanced or Metastatic Non-small Cell Lung CancerSHR-8068，adebelizumab and platinum-based chemotherapytislelizumab, and platinum-based chemotherapy
brief summary
This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.
started
Oct 22, 2025
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Nov 18, 2025
official title
A Randomized, Open-label, Controlled, Multicenter Phase III Study of SHR-8068 Combined With Adebrelimab and Platinum-based Chemotherapy Versus Tislelizumab Combined With Platinum-based Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol